Last reviewed · How we verify
Toxoplasmosis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Azo Gantanol | SULFAMETHOXAZOLE | Pfizer | Sulfonamide Antimicrobial [EPC] | 1973-01-01 | ||
| Sulfadiazine | SULFADIAZINE | Eli Lilly | Sulfonamide Antibacterial [EPC] | 5-hydroxytryptamine receptor 2A | 1941-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Eli Lilly · 1 drug in Toxoplasmosis
- Pfizer · 1 drug in Toxoplasmosis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Toxoplasmosis:
- Toxoplasmosis treatment updates — RSS
- Toxoplasmosis treatment updates — Atom
- Toxoplasmosis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Toxoplasmosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/toxoplasmosis. Accessed 2026-06-10.
Related
- Toxoplasmosis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing